BioSpace News Archive

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient population Compelling NASH-RX trial result could potentially lead to accelerated FDA approval and/or partnership opportunities and fulfill an acute unmet medical need NORCROSS, Ga., June 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, the leading developer of therapeutics that targe

BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a clinical trial application (CTA) to begin a Phase I/IIa, first-in-human study of BI-1808, a monoclonal a

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240. RTX-240 is an allogeneic cellular therapy for the treatment of patients with relapsed/refracto

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced initiation of development of a new product candidate, OPN-019.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central

The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization, announced today the recipients of its 2020 research grants and grant extensions. This year, 10 gra

Silicon Valley, California and Calgary, Alberta based precision medicine technology pioneer PROTXX and the University of Alberta in Edmonton, Alberta today announced a new research collaboration that will leverage the PROTXX precision healthcare platform for remote personalized health management of

Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis

Health plans are playing a leadership role in combatting the nation’s opioid crisis due to growing concerns around medication misuse, addiction and overdoses. To help health insurance providers in these efforts, DisposeRx, Inc ., the product leader in at-home medication disposal solutions, has created a new education and engagement pr

Evecxia, Inc., a biopharmaceutical company focused on the treatment of neuropsychiatric diseases, today announced it has completed its Series A financing, raising $6.5m. This financing will fund the early development of EVX-101, the Company’s lea